Although multiple clinical trials with BTK inhibitors in pSS are still recruiting and results are awaited (NCT04035668; NCT04186871), the limited effectiveness of BTK inhibition in a recent study might be partly explained by our current findings of unaltered BTK levels and BCR signaling activity in circulating B cells from pSS patients at diagnosis [50,51]. This evidence concerns the gene BCR and peeling skin syndrome.